clinical trial · NCT07775261
A Trial of Lu AH69593 in Healthy Participants
H. Lundbeck A/S·phase1·not yet recruiting·n = 46
Healthy ParticipantsLu AH69593ItraconazoleCarbamazepineMidazolam
brief summary
This trial will evaluate the effects of itraconazole (Part A) and, carbamazepine (Part B) on Lu AH69593, and the effect of Lu AH69593 on midazolam (Part C) in adult healthy participants. The main goals of this trial are to learn about 1. the effect of other medicines on Lu AH69593 2. the pharmacokinetic parameters of Lu AH69593 (how the drug is absorbed, distributed, and processed by the body), and 3. the safety and tolerability of Lu AH69593.
started
Aug 27, 2026
primary completion
Nov 4, 2026
completion
Nov 6, 2026
last updated
Aug 20, 2026
official title
Interventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4/5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4/5 Substrate in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol